Liu, Yingmiao

Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study

Lampert, E. J., Zimmer, A., Padget, M., Cimino-Mathews, A., Nair, J. R., Liu, Y., Swisher, E. M., Hodge, J. W., Nixon, A. B., Nichols, E., et al. (2020) · Clinical Cancer Research

PARP inhibition in cancer therapyOvarian cancer diagnosis and treatment

Cited by 220

Reversal of cocaine sensitization-induced behavioral sensitization normalizes GAD67 and GABAA receptor α2 subunit expression, and PKC ζ activity

Chen, Q., Lee, T. H., Wetsel, W. C., Sun, Q.-A., Liu, Y., Davidson, C., Xiong, X., Ellinwood, E. H., & Zhang, X. (2007) · Biochemical and Biophysical Research Communications

Neurotransmitter Receptor Influence on BehaviorNeuroscience and Neuropharmacology Research

Cited by 30

A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)

Clarke, J. M., Blobe, G. C., Strickler, J. H., Uronis, H. E., Zafar, S. Y., Morse, M., Dropkin, E., Howard, L., O’Neill, M., Rushing, C. N., et al. (2019) · Cancer Chemotherapy and Pharmacology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 18